Sutro Biopharma (NASDAQ:STRO) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Sutro Biopharma (NASDAQ:STRO) in a research report sent to investors on Monday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2024 earnings at ($0.68) EPS, FY2024 earnings at ($2.75) EPS, Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.57) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($3.47) EPS and FY2028 earnings at ($3.03) EPS.

STRO has been the subject of a number of other research reports. Piper Sandler restated an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a research report on Friday, October 11th. Truist Financial cut their price objective on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Finally, JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Monday, September 16th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.14.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock opened at $2.53 on Monday. Sutro Biopharma has a 1-year low of $2.13 and a 1-year high of $6.13. The company’s fifty day simple moving average is $3.64 and its 200-day simple moving average is $3.81. The stock has a market capitalization of $208.62 million, a PE ratio of -1.57 and a beta of 1.17.

Institutional Investors Weigh In On Sutro Biopharma

A number of institutional investors have recently added to or reduced their stakes in STRO. Gladius Capital Management LP purchased a new stake in shares of Sutro Biopharma in the third quarter valued at $28,000. ProShare Advisors LLC increased its stake in shares of Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after buying an additional 5,373 shares during the period. Virtu Financial LLC bought a new position in Sutro Biopharma in the third quarter worth approximately $77,000. Intech Investment Management LLC purchased a new stake in shares of Sutro Biopharma during the third quarter valued at about $91,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Sutro Biopharma in the 1st quarter worth $92,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.